Elite Pharmaceuticals receives FDA approval for generic Requip XL (ropinirole ER) tablets

ELITE PHARMACEUTICALS INC /NV/

FDA approved ANDA for generic Requip XL (Ropinirole Extended-Release Tablets USP) in 2,4,6,8,12 mg strengths.
Product indicated for Parkinson's disease; will be marketed under Elite Laboratories label.
IQVIA data: U.S. branded & generic sales of $10M for 12 months ending September 2025.
Approval enables Elite to compete in the ropinirole ER tablet market.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.